C12N 2760/18743
Viral genome or elements thereof as genetic vector
Official title: viral genome or elements thereof as genetic vector
C12N2760/18743 (Viral genome or elements thereof as genetic vector) appears on 20 US grants and 34 published applications in this corpus.
Search patents in C12N- Granted patents
- 20
- Published applications
- 34
- Assignees
- 20
- Inventors
- 45
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 2 |
| 2008 | 1 | 1 |
| 2009 | 0 | 1 |
| 2010 | 1 | 0 |
| 2011 | 1 | 1 |
| 2012 | 0 | 1 |
| 2013 | 1 | 2 |
| 2014 | 0 | 2 |
| 2015 | 1 | 2 |
| 2016 | 1 | 0 |
| 2017 | 3 | 3 |
| 2018 | 0 | 2 |
| 2019 | 1 | 2 |
| 2020 | 3 | 2 |
| 2021 | 1 | 2 |
| 2022 | 0 | 1 |
| 2023 | 3 | 2 |
| 2024 | 1 | 3 |
| 2025 | 1 | 2 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/PIV3 F protein and uses thereof2 Jun 2026US 12,643,925 B2The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Oncolytic viruses for sensitizing tumor cells to killing by natural killer cells27 May 2025US 12,312,393 B2University of Central Florida Research Foundation, Inc.
- Recombinant human parainfluenza virus type 1 expressing a chimeric RSV/HPIV1 f protein and uses thereof25 Jun 2024US 12,018,051 B2The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Oncolytic viruses for sensitizing tumor cells to killing by natural killer cells27 Jun 2023US 11,684,637 B2University of Central Florida Research Foundation, Inc.
- Recombinant human/bovine parainfluenza virus 1 (HPIV1) expressing a chimeric RSV/HPIV1 F protein and uses thereof28 Feb 2023US 11,591,372 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Anticancer agent, pharmaceutical composition for cancer treatment, kit, and activator20 Aug 2026US 2026/0240929 A1BioComo Incorporation
- Piv5-based covid-19 vaccine12 Mar 2026US 2026/0069674 A9University of Georgia Research Foundation, Inc.
- Piv5-based covid-19 vaccine16 Oct 2025US 2025/0319176 A1University of Georgia Research Foundation, Inc.
- Viral vectors3 Jul 2025US 2025/0213674 A1City, University of London
- Recombinant human/bovine parainfluenza virus 3 (b/hpiv3) expressing a chimeric rsv/piv3 f protein and uses thereof19 Sep 2024US 2024/0309053 A1The United States of America, as represented by the Secretary, Department of Health and Human Servic
Most cited
By later US patents
- Rescue of mumps virus from cDNA5US 7,361,496 B1Wyeth · 2008
- Recovery of recombinant human parainfluenza virus type 2 (HYPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens4US 8,367,074 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2013
- Recombinant human/bovine parainfluenza virus 1 (HPIV1) expressing a chimeric RSV/HPIV1 F protein and uses thereof2US 11,591,372 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2023
- Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/BPIV3 F protein and uses thereof1US 10,654,898 B2The United States of America, as represented by the Secretary, Department of Health and Human Serices · 2020
- Parainfluenza virus 5 based vaccines1US 10,752,916 B2University of Georgia Research Foundation, Inc. · 2020